IRTC · Insider Trading
iRhythm Holdings, Inc. Common Stock
Every open-market purchase and sale reported by IRTC officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | Daniel G. Wilson | Chief Financial Officer | Sell | −773 | −$94.17K |
| 2026-08-11 | Quentin S. Blackford | President and CEO | MIXED | +21,675 | −$3.35M |
| 2026-08-11 | Patrick Michael Murphy | CBO and CLO | MIXED | +6,496 | −$884.16K |
| 2026-08-11 | Minang Turakhia | CHIEF MED/SCI OFCR EVP ADVTECH | MIXED | +6,496 | −$884.15K |
| 2026-08-11 | Chad Patterson | CHIEF COMM & PRODUCT OFFICER | MIXED | +6,496 | −$884.17K |
| 2026-08-11 | Sumi Shrishrimal | EVP, Chief Risk Officer | MIXED | +4,334 | −$669.64K |
| 2026-08-04 | Mervin Smith | EVP Strategic Business Ops | Sell | −617 | −$75.35K |
| 2026-08-04 | Chad Patterson | CHIEF COMM & PRODUCT OFFICER | Sell | −2,712 | −$331.19K |
| 2026-08-04 | Julianne Rodda | EVP, CHIEF PEOPLE OFFICER | Sell | −2,112 | −$257.92K |
| 2026-07-06 | Sean Clinton Freeman | EVP, Strategy & Corp Devt | Sell | −918 | −$114.48K |
| 2026-07-06 | Minang Turakhia | CHIEF MED/SCI OFCR EVP ADVTECH | Sell | −1,423 | −$177.46K |
| 2026-06-03 | Sumi Shrishrimal | EVP, Chief Risk Officer | MIXED | −1,583 | −$172.78K |
| 2026-06-03 | Marc Wade Rosenbaum | Chief Accounting Officer | MIXED | −551 | −$61.64K |
| 2026-06-01 | Quentin S. Blackford | President and CEO | A | +178 | +$17.23K |
| 2026-06-01 | Chad Patterson | CHIEF COMM & PRODUCT OFFICER | A | +177 | +$17.14K |
| 2026-06-01 | Minang Turakhia | CHIEF MED/SCI OFCR EVP ADVTECH | A | +137 | +$13.26K |
| 2026-06-01 | Sean Clinton Freeman | EVP, Strategy & Corp Devt | A | +273 | +$26.43K |
| 2026-05-29 | Kevin C Oboyle | Director | A | +1,573 | — |
| 2026-05-29 | Merz Cathleen Noel Bairey | Director | A | +1,573 | — |
| 2026-05-29 | Bruce G. Bodaken | Director | A | +1,573 | — |
| 2026-05-29 | Abhijit Y Talwalkar | Director | A | +1,573 | — |
| 2026-05-29 | Karen K McGinnis | Director | A | +1,573 | — |
| 2026-05-29 | Brian B Yoor | Director | A | +1,573 | — |
| 2026-05-29 | Karen Ling | Director | A | +1,573 | — |
| 2026-05-12 | Abhijit Y Talwalkar | Director | MIXED | — | −$569.54K |
| 2026-05-05 | Brian Lee Lawrence | Chief Technology Officer | Sell | −1,014 | −$122.49K |
| 2026-03-19 | Jason H Patten | Director | A | +2,218 | — |
| 2026-03-17 | Mervin Smith | EVP Strategic Business Ops | Sell | −2,585 | −$295.47K |
| 2026-03-03 | Patrick Michael Murphy | CBO and CLO | Sell | −4,357 | −$559.62K |
| 2026-03-03 | Minang Turakhia | CHIEF MED/SCI OFCR EVP ADVTECH | Sell | −4,027 | −$517.26K |
| 2026-03-03 | Marc Wade Rosenbaum | Chief Accounting Officer | Sell | −816 | −$104.81K |
| 2026-03-03 | Mervin Smith | EVP Strategic Business Ops | Sell | −1,352 | −$173.65K |
| 2026-03-03 | Daniel G. Wilson | Chief Financial Officer | Sell | −3,395 | −$436.08K |
| 2026-03-03 | Sumi Shrishrimal | EVP, Chief Risk Officer | Sell | −2,830 | −$363.48K |
| 2026-03-03 | Quentin S. Blackford | President and CEO | Sell | −13,813 | −$1.77M |
| 2026-03-03 | Chad Patterson | CHIEF COMM & PRODUCT OFFICER | Sell | −4,444 | −$570.80K |
| 2026-02-27 | Chad Patterson | CHIEF COMM & PRODUCT OFFICER | A | +10,870 | — |
| 2026-02-27 | Mervin Smith | EVP Strategic Business Ops | A | +6,689 | — |
| 2026-02-27 | Patrick Michael Murphy | CBO and CLO | A | +7,024 | — |
| 2026-02-27 | Brian Lee Lawrence | Chief Technology Officer | A | +6,689 | — |
| 2026-02-27 | Sumi Shrishrimal | EVP, Chief Risk Officer | A | +5,518 | — |
| 2026-02-27 | Daniel G. Wilson | Chief Financial Officer | A | +8,361 | — |
| 2026-02-27 | Quentin S. Blackford | President and CEO | A | +31,842 | — |
| 2026-02-27 | Sean Clinton Freeman | EVP, Strategy & Corp Devt | A | +7,525 | — |
| 2026-02-27 | Minang Turakhia | CHIEF MED/SCI OFCR EVP ADVTECH | A | +10,034 | — |
| 2026-02-27 | Marc Wade Rosenbaum | Chief Accounting Officer | A | +2,508 | — |
| 2026-02-26 | Sumi Shrishrimal | EVP, Chief Risk Officer | MIXED | +5,077 | −$841.90K |
| 2026-02-26 | Marc Wade Rosenbaum | Chief Accounting Officer | MIXED | +4,413 | −$649.60K |
| 2026-02-26 | Minang Turakhia | CHIEF MED/SCI OFCR EVP ADVTECH | MIXED | +7,256 | −$1.06M |
| 2026-02-26 | Daniel G. Wilson | Chief Financial Officer | MIXED | +4,224 | −$702.55K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Quentin S. Blackford | President and CEO | 252,867 | $22.54M |
| Patrick Michael Murphy | CBO and CLO | 69,699 | $6.21M |
| Chad Patterson | CHIEF COMM & PRODUCT OFFICER | 62,125 | $5.54M |
| Minang Turakhia | CHIEF MED/SCI OFCR EVP ADVTECH | 60,116 | $5.36M |
| Sumi Shrishrimal | EVP, Chief Risk Officer | 44,621 | $3.98M |
| Daniel G. Wilson | Chief Financial Officer | 34,987 | $3.12M |
| Mervin Smith | EVP Strategic Business Ops | 22,410 | $2.00M |
| Abhijit Y Talwalkar | Director | 21,872 | $1.95M |
| Brian Lee Lawrence | Chief Technology Officer | 20,154 | $1.80M |
| Julianne Rodda | EVP, CHIEF PEOPLE OFFICER | 18,201 | $1.62M |
| Marc Wade Rosenbaum | Chief Accounting Officer | 16,155 | $1.44M |
| Bruce G. Bodaken | Director | 14,211 | $1.27M |
| Mark J Rubash | Director | 13,788 | $1.23M |
| Sean Clinton Freeman | EVP, Strategy & Corp Devt | 13,641 | $1.22M |
| Ralph Snyderman | Director | 13,288 | $1.18M |
| Karen Ling | Director | 11,141 | $992.89K |
| Merz Cathleen Noel Bairey | Director | 10,546 | $939.86K |
| Brian B Yoor | Director | 7,171 | $639.08K |
| Jason H Patten | Director | 4,436 | $395.34K |
| Kevin C Oboyle | Director | 3,608 | $321.54K |
| Karen K McGinnis | Director | 3,608 | $321.54K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the IRTC quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.